 The first six months of 2021 have been transformational, 4D Pharma PLC, the developer of live biotherapeutic drugs that interact with the human microbiome said as it posted interim results. The key milestone from a capital markets perspective, was the companys Nasdaq listing in March via special acquisition vehicle, which now provides a significantly larger investor base. 